Genetic predisposition and treatment-related leukemia

Medical and Pediatric Oncology

Volumn 36, Issue 5, 2001, Pages 541-548

  Perentesis, Jhon Peter ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Genetic polymorphisms; Leukemia etiology; Secondary leukemia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACYLTRANSFERASE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BIOFLAVONOID; CYSTATHIONINE BETA SYNTHASE; CYTOCHROME P450 1A1; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; EPIPODOPHYLLOTOXIN; GLUTATHIONE TRANSFERASE; MYELOPEROXIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; OXIDOREDUCTASE; QUINONE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SUSCEPTIBILITY; CANCER THERAPY; CONFERENCE PAPER; GENETIC DAMAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HUMAN; LEUKEMIA; METASTASIS; NEUROFIBROMATOSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA; POLYMORPHISM, GENETIC;

EID: 0035055918     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.1127     Document Type: Conference Paper

References (83)

1. Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin disease and non-Hodgkin lymphoma
2. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors
3. Neuroblastoma and treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering experience and a literature review
4. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease
5. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centers
6. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment
7. Increase therapy-related leukemia secondary to breast cancer
8. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome
9. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
10. Therapy-related acute leukemia
11. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies
12. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
13. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation
14. Therapy-related leukemia and myelodysplastic syndrome in breast cancer patients treated with cyclophosphamide or anthracyclines
15. Therapy-related AML after successful chemotherapy with low dose etoposide for virus-associated hemophagocytic syndrome
16. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no. 5 and 7
17. Morphologic and cytochemical observations on the overt leukemic phase of therapy-related leukemia
18. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: Correlation between chromosomal abnormalities and prior therapy
19. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung
20. Acute lymphoblastic leukaemia with t(4;11) follows neuroblastoma: A late effect of treatment?
21. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
22. Secondary leukemias induced by topoisomerase-targeted drugs
23. The hereditary basis of human leukemia
24. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1
25. The p53 gene in pediatric therapy-related leukemia and myelodysplasia
26. The glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
27. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism
28. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion
29. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect
30. Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia
31. Glutathione S-transferase gene deletions in myelodysplasia
32. Glutathione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukaemia
33. Glutathione Stransferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens
34. Glutathione S-transferase polymorphisms in children with myeloid leukemia: A Children's Cancer Group study
35. Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia
36. Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukaemia
37. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood AML: A Children's Cancer Group study
38. Glutathione S-transferase genotypes in children who develop treatment- related acute myeloid malignancies
39. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia
40. Expression of mu class glutathione S-transferase correlates with event- free survival in childhood acute lymphoblastic leukemia
41. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: A case-control study
42. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C → T mutation and rapid fractional excretion of chlorzoxazone
43. Biomarkers of leukemia risk: Benzene as a model
44. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H: Quinone oxidoreductase 1 (NQO1) to benzene toxicity
45. Modulation of the toxicity and macromolecular binding of benzene metabolites by NAD(P)H: Quinone oxidoreductase in transfected HL-60 cells
46. Enhancement of myeloid cell growth by benzene metabolites via the production of active oxygen species
47. Benzene, NQO1, and genetic susceptibility to cancer
48. Increased translocations and aneusomy in chromosomes 8 and 21 among workers exposed to benzene
49. Hydroquinone, a benzene metabolite, increases the level of aneusomy of chromosomes 7 and 8 in human CD34-positive blood progenitor cells
50. Benzene increases aneuploidy in the lymphocytes of exposed workers: A comparison of data obtained by fluorescence in situ hybridization in interphase and metaphase cells
51. Increased aneusomy and long arm deletion of chromosomes 5 and 7 in the lymphocytes of Chinese workers exposed to benzene
52. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H: Quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
53. Why is age such an important independent prognostic factor in acute lymphoblastic leukemia?
54. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots
55. Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias
56. Maternal diet and infant leukemia: A role for DNA topoisomerase II inhibitors?
57. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia
58. A lack of a functional NAD(P)H: Quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators
59. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
60. Association of CYP3A4 genotype with treatment-related leukemia
61. An Alu element in the myeloperoxidase promoter contains a composite SP1- thyroid hormone-retinoic acid response element
62. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia
63. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults
64. Down syndrome and leukemia
65. Epidemiology of Down syndrome and childhood acute leukemia
66. Down syndrome and acute leukemia in children: A 10-year retrospective survey from Childrens Cancer Study Group
67. Down syndrome and acute myeloid leukemia. Lessons learned from experience with high-dose Ara-C containing regimens
68. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin
69. Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin
70. Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Quebec, Canada)
71. Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms
72. Risk of childhood leukemia associated with diagnostic irradiation and polymorphisms in DNA repair genes
73. Preconceptional paternal exposure to pesticides and increased risk of childhood leukaemia
74. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms
75. Genetic susceptibility to childhood acute lymphoblastic leukemia
76. Genetic polymorphisms of N-acetyltransferases 1 and 2 and gene-gene interaction in the susceptibility to childhood acute lymphoblastic leukemia
77. The genetic clock and the age of the founder effect in growing populations: A lesson from French Canadians and Ashkenazim
78. Do mutations at the glycophorin A locus in patients treated for childhood Hodgkin's disease predict secondary leukaemia?
79. Glycophorin A mutations and risk of secondary leukaemia in patients treated for childhood acute lymphoblastic leukaemia
80. RAS mutations in patients following cytotoxic therapy for lymphoma
81. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma
82. Predictive value of clonality assays in patients with non-Hodgkin's lymphoma undergoing autologous bone marrow transplant: A single institution study
83. dbSNP: A database of single nucleotide polymorphisms